Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

EU loses no time in appointing new Commission:

This article was originally published in Clinica

Executive Summary

Following the withdrawal at the end of October by the incoming president of the European Commission, Jose Manuel Dur-o Barroso, of his proposed team of new commissioners, just days before they were due to take up office, a new team has now been accepted. The Council of the European Union adopted a decision on November 19 appointing the president and members of the Commission. The decision will take effect on November 22 and the team will be in office until October 31, 2009. Following the upheaval, there are two new faces in the team - Franco Frattini of Italy (justice, freedom and security) and Andris Piebalgs of Latvia (energy). One Commissioner, Lazlo Kovacs of Hungary, has a new portfolio (taxation and the customs union). The team was approved by the European Parliament on November 18. There are no alterations to the key people for the medical devices and diagnostics industries: Gunter Verheugen remains and enterprise and industry commissioner and Markos Kyprianou as health and consumer protection commissioner.

You may also be interested in...



Chinese Firms Up Their Game In Novel Flu Antiviral Development

Joincare Pharmaceutical and partner TaiGen Biotechnology tout preliminary Phase III results in uncomplicated acute influenza for TG-1000, a homegrown follower of Shionogi/Roche’s oral antiviral Xofluza. Novel antivirals for flu were hotly pursued by Chinese developers throughout 2023.

Quotable: Words Of Wisdom From Our Recent APAC Coverage

Scrip's APAC team selects notable quotes from recent interviews, conferences and other coverage to highlight the views of senior executives and officials on the major topics facing the biopharma sector in the region.

Generic Or Innovator? Sandoz Sues CMS Over Potential Change In Rebate Classification

Sandoz argued against paying higher rebates for two of its drugs via the Centers for Medicare and Medicaid Services’ Medicaid drug rebate program in a US court six years after the suggestion was first made.

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

MT060273

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel